Amgen Manufacturing, Limited

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Haemodialysis Patients Switching From Aranesp to Biosimilar

Completed

Conditions: Anaemia

First Posted Date: 2014-07-16

Last Posted Date: 2016-02-08

Lead Sponsor: Amgen

Target Recruit Count: 272

Registration Number: NCT02191150

Locations: 🇪🇸
Research Site, Zamora, Castilla León, Spain

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis in Men

Interventions: Drug: Placebo
Biological: Romosozumab

First Posted Date: 2014-07-10

Last Posted Date: 2019-05-28

Lead Sponsor: Amgen

Target Recruit Count: 245

Registration Number: NCT02186171

Locations: 🇨🇭
Research Site, Zurich, Switzerland

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Phase 2

Terminated

Conditions: Stomach Neoplasms

Interventions: Drug: AMG 337

First Posted Date: 2013-12-20

Last Posted Date: 2017-07-02

Lead Sponsor: Amgen

Target Recruit Count: 60

Registration Number: NCT02016534

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

Phase 2

Completed

Conditions: Psoriatic Arthritis
Psoriasis Arthropatica
Psoriasis

Interventions: Drug: Apremilast
Drug: Placebo

First Posted Date: 2013-11-20

Last Posted Date: 2020-05-07

Lead Sponsor: Amgen

Target Recruit Count: 254

Registration Number: NCT01988103

Locations: 🇯🇵
Yano Hifuka Hinyokika Clini, Fukuoka-shi, Fukuoka, Japan
🇯🇵
Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵
TASHIRO Dermatological Clinic, Iizuka-shi, Fukuoka, Japan

and more 52 locations

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Zoledronic acid
Drug: Denosumab
Drug: Placebo to Denosumab
Drug: Standard Chemotherapy
Drug: Placebo to Zoledronic Acid

First Posted Date: 2013-09-26

Last Posted Date: 2021-10-25

Lead Sponsor: Amgen

Target Recruit Count: 226

Registration Number: NCT01951586

Locations: 🇬🇧
Research Site, Preston, United Kingdom

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2013-06-20

Last Posted Date: 2022-11-14

Lead Sponsor: Amgen

Target Recruit Count: 22

Registration Number: NCT01881789

Locations: 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Providence St. Joseph's Hospital, Burbank, California, United States
🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States

and more 11 locations

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Dexamethasone

First Posted Date: 2013-04-16

Last Posted Date: 2020-07-13

Lead Sponsor: Amgen

Target Recruit Count: 65

Registration Number: NCT01832727

Locations: 🇫🇷
CHRU, Hopital Huriez - Department of Hematology, Lille CEDEX, France
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇫🇷
CHU Hotel Dieu - Service d'Hematologie Clinique, NANTES Cedex, France

and more 10 locations

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Phase 3

Completed

Conditions: Hyperlipidemia

Interventions: Biological: Evolocumab
Drug: Ezetimibe
Drug: Placebo to Ezetimibe
Drug: Placebo to Evolocumab
Drug: Rosuvastatin
Drug: Simvastatin
Drug: Atorvastatin

First Posted Date: 2013-01-09

Last Posted Date: 2022-11-08

Lead Sponsor: Amgen

Target Recruit Count: 2067

Registration Number: NCT01763866

Locations: 🇬🇧
Research Site, Whitby, United Kingdom

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Phase 1

Terminated

Conditions: Diabetes Mellitus

Interventions: Drug: AMG 151
Other: Placebo

First Posted Date: 2012-12-24

Last Posted Date: 2013-04-22

Lead Sponsor: Amgen

Target Recruit Count: 5

Registration Number: NCT01755442

Locations: 🇺🇸
Research Site, San Diego, California, United States

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Biological: Abrilumab
Drug: Placebo

First Posted Date: 2012-09-27

Last Posted Date: 2019-06-27

Lead Sponsor: Amgen

Target Recruit Count: 359

Registration Number: NCT01694485

Locations: 🇬🇧
Research Site, Norwich, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy